Ginkgo Bioworks Holdings (DNA) Receivables (2020 - 2026)

Ginkgo Bioworks Holdings has reported Receivables for 7 years, with the latest figure at $19.8 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 24.64% year-over-year to $19.8 million; the trailing twelve-month figure through Mar 2026 stood at $19.8 million (down 24.64% YoY), and the FY2025 full-year result was $24.0 million, up 9.92% from the prior year.
• Receivables for Q1 2026 stood at $19.8 million, down from $24.0 million in the prior quarter.
• The five-year high for Receivables was $178.1 million in Q2 2022, with the low at $302000.0 in Q2 2024.
• Historically, Receivables has averaged $50.3 million across 5 years, with a median of $26.3 million in 2025.
• Annual changes were most pronounced in 2024 — Receivables sank 99.56% — and 2025, when it surged 10844.37%.
• Ginkgo Bioworks Holdings' Receivables stood at $1.6 million in 2022, then surged by 595.89% to $10.8 million in 2023, then soared by 101.6% to $21.9 million in 2024, then advanced by 9.92% to $24.0 million in 2025, then fell by 17.53% to $19.8 million in 2026.
• The last three Receivables figures came in at $19.8 million (Q1 2026), $24.0 million (Q4 2025), and $32.6 million (Q3 2025), per Business Quant data.